Skip to content
VuFind
    • English
    • Deutsch
    • Español
    • Français
    • Italiano
    • 日本語
    • Nederlands
    • Português
    • Português (Brasil)
    • 中文(简体)
    • 中文(繁體)
    • Türkçe
    • עברית
    • Gaeilge
    • Cymraeg
    • Ελληνικά
    • Català
    • Euskara
    • Русский
    • Čeština
    • Suomi
    • Svenska
    • polski
    • Dansk
    • slovenščina
    • اللغة العربية
    • বাংলা
    • Galego
    • Tiếng Việt
    • Hrvatski
    • हिंदी
    • Հայերէն
    • Українська
    • Sámegiella
    • Монгол
Napredno
  • Response to the letter by Prof...
  • Citiraj
  • Pošljite SMS
  • Pošljite email
  • Natisni
  • Izvozi zadetek
    • Izvozi v RefWorks
    • Izvozi v EndNoteWeb
    • Izvozi v EndNote
  • Permanent link
Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor

Bibliografske podrobnosti
Main Authors: Leber, W, Lammel, O, Panovska-Griffiths, J, Czypionka, T
Format: Journal article
Jezik:English
Izdano: Elsevier 2021
  • Zaloga
  • Opis
  • Podobne knjige/članki
  • Knjižničarski pogled

Podobne knjige/članki

  • Response to the letter by Prof Jonathan Deeks to the Lancet EClinicalMedicine editor
    od: Werner Leber, et al.
    Izdano: (2021-10-01)
  • Corrigendum to ‘Oral Azvudine for hospitalised patients with COVID-19 and pre-existing conditions: a retrospective cohort study.’ [EClinicalMedicine 59 (2023) 101981]
    od: Yuming Sun, et al.
    Izdano: (2023-08-01)
  • Corrigendum to “Real-world long-term outcomes in individuals at clinical risk for psychosis: The case for extending duration of care” [EClinicalMedicine 28 (2020) 100,578]
    od: Paolo Fusar-Poli, et al.
    Izdano: (2021-02-01)
  • Corrigendum to Antiviral effect of high-dose ivermectin in adults with COVID-19: A proof-of-concept randomized trial [EClinicalMedicine 37 (2021) 100,959]”
    od: Alejandro Krolewiecki, et al.
    Izdano: (2021-09-01)
  • Corrigendum to “Nitazoxanide superiority to placebo to treat moderate COVID-19 – A Pilot prove of concept randomized double-blind clinical trial.” [EClinicalMedicine 37 (2021) 100981]
    od: Vinicius Fontanesi Blum, MD, MSc, et al.
    Izdano: (2021-11-01)

Iskalne možnosti

  • Iskalna zgodovina
  • Napredno iskanje

Poišči več

  • Prelistaj katalog
  • Po abecedi
  • Explore Channels
  • Obvezna literatura
  • Novi knjige/članki

Potrebujete pomoč?

  • Navodila za iskanje
  • Vprašaj knjižničarja
  • Pogosta vprašanja